Background: Eligibility to immunotherapy is based on the determination of IgE reactivity to a specific allergen by means of skin prick or in vitro testing. Biomarkers predicting the likelihood of clinical improvement during immunotherapy would significantly improve patient selection. Methods: Proteins were differentially assessed by using 2-dimensional differential gel electrophoresis and label-free mass spectrometry in pretreatment sera obtained from clinical responders and nonresponders within a cohort of 82 patients with grass pollen allergy receiving sublingual immunotherapy or placebo. Functional studies of Fetuin-A (FetA) were conducted by using gene silencing in a mouse asthma model, human dendritic cell in vitro stimulation assays, and surface plasmon resonance. Results: Analysis by using quantitative proteomics of pretreatment sera from patients with grass pollen allergy reveals that high levels of O-glycosylated sialylated FetA isoforms are found in patients exhibiting a strong decrease in rhinoconjunctivitis symptoms after sublingual immunotherapy. Although FetA is involved in numerous inflammatory conditions, its potential role in allergy is unknown. In vivo silencing of the FETUA gene in BALB/c mice results in a dramatic upregulation of airway hyperresponsiveness, lung resistance, and T H 2 responses after allergic sensitization to ovalbumin. Both sialylated and nonsialytated FetA bind to LPS, but only the former synergizes with LPS and grass pollen or mite allergens to enhance the Toll-like receptor 4-mediated proallergic properties of human dendritic cells. Allergen immunotherapy (AIT) through the subcutaneous or sublingual routes is currently established as a safe and efficacious treatment for type I (IgE-mediated) respiratory allergies to pollen and house dust mite allergens. [1] [2] [3] Potential biomarkers of efficacy for AIT are generating considerable interest because they could be used to inform the physician's decisions during treatment. [4] [5] [6] [7] [8] Biomarkers are commonly defined as indicators of either normal or pathogenic processes or of responses to a therapeutic intervention, which can be objectively measured in readily accessible biological samples. 4 The search for biomarkers of efficacy has been thus far based on the paradigm that AIT acts by shifting allergen-specific CD4 1 T-cell responses from a T H 2 to a T H 1/regulatory T-cell pattern. 7, 9, 10 Thus clinically efficacious AIT has been related to the induction of allergen-specific regulatory T cells associated with IgG 4 responses encompassing high-affinity blocking antibodies competing with IgE for allergen binding. [11] [12] [13] Recently, we also reported that early onset of clinical efficacy is correlated with induction in peripheral blood of monocyte-derived regulatory dendritic cells, driving the differentiation of regulatory T cells (DCRegs) concomitantly with a decrease in proallergic type 2 dendritic cells (DCs; ie, dendritic cells driving the differentiation of T H 2 cells [DC2s]). 14, 15 Although all those biological changes represent candidate follow-up markers reflecting efficacy after AIT has been initiated, patient selection would further benefit from identification of biomarkers predicting the likelihood of clinical responsiveness before starting treatment. 8 Patients' eligibility to immunotherapy is currently based on the determination of IgE reactivity to a specific allergen by means of skin prick or in vitro testing. In addition, patients with either severe rhinoconjunctivitis symptoms, 16, 17 high basophil responsiveness to allergens, 18 or increased allergen-specific IgE titers [19] [20] [21] [22] before treatment appear more likely to benefit from AIT. As of today, however, no marker of AIT efficacy has been firmly established that could be used at an individual patient level to predict positive immunotherapy outcomes.
Herein we searched for such biomarkers of sublingual immunotherapy efficacy in sera from 82 patients with grass pollen allergy enrolled in a double-blind placebo-controlled study performed in an exposure challenge chamber. 23 Using comparative proteomics, we provide evidence for increased O-linked sialylation of Fetuin-A (FetA) in sera collected before treatment from patients exhibiting clinical responses when compared with low responders. We also demonstrate that FetA plays a role in the regulation of allergic inflammation and, furthermore, that sialylated FetA, but not its desialylated counterpart (AsialoFetA), enhances Toll-like receptor 4 (TLR4)-mediated allergic inflammation.
METHODS
Clinical samples from the VO56.07A pollen chamber study Details of the VO56.07A clinical study have been published elsewhere. 23 Briefly, 82 patients with grass pollen allergy were randomized to receive either a grass pollen (n 5 42) or placebo (n 5 40) tablet once daily for 4 months through the sublingual route. Patients were exposed to grass pollen grains in a chamber (Allergy Center in Vienna West, Austria) before treatment, as well as after 1 week and 1, 2, and 4 months of treatment. 23 Clinical responses were evaluated after allergen challenge for each patient as percentages of improvement in Average Rhinoconjunctivitis Total Symptom Scores (ARTSSs) measured as described elsewhere. 23 As a first step, the median percentage of ARTSS improvement in the active group after treatment was used as an arbitrary threshold to identify clinical responders, with patients exhibiting a 43.9% or greater ARTSS improvement considered responders and those with lower improvement considered nonresponders. Based on this threshold, 4 patient subgroups were defined, including active responders (ARs; n 5 21), active nonresponders (ANRs; n 5 21), placebo responders (PRs; ie, patients exhibiting clinical improvement unrelated to treatment efficacy; n 5 7), and placebo nonresponders (PNRs; n 5 33). Sera were collected from patients before and after AIT and kept frozen at 2808C until use. All biological analyses were performed on samples coded to the operators.
Identification and characterization of FetA and desialylated FetA
Proteomes were assessed by using quantitative proteomics in serum samples from clinical responders and nonresponders. Serum sample depletion, 2-dimensional differential gel electrophoresis (2D-DiGE), and mass spectrometry (MS) of differentially expressed spots, as well as label-free MS-based proteomics, are described in details in the Methods section in this article's Online Repository at www.jacionline.org.
Purification and MS analysis of human and murine FetA, as well as the FetA desialylation procedure, are described in the Methods section in this article's Online Repository. Functional properties of FetA were analyzed in ovalbumin (OVA)-or grass pollen-sensitized BALB/c mice after in vivo gene silencing before measurement of airway hyperresponsiveness and lung resistance. FetA and AsialoFetA were compared for their capacity to activate human monocyte-derived dendritic cells (MoDCs) alone or in combination with LPS and allergen extracts. LPS-FetA-TLR4 interactions were measured by using surface plasmon resonance. All in vivo and in vitro functional assays are described in the Methods section in this article's Online Repository.
Statistics
Data are expressed as means 6 SEMs. Differences in protein expression or peptide abundance, as observed by using 2D-DiGE analysis or label-free MS experiments, respectively, were analyzed for statistical significance by applying an ANOVA P value threshold of .01, with a fold change filter of 1.5 or greater. Statistics on proteomic data were performed with the SameSpots or Progenesis LC-MS software from Nonlinear Dynamics (Newcastle upon Tyne, United Kingdom). Correlation analyses were performed with the nonparametric Spearman test. P values of less than .05 were considered significant. Statistical differences between groups were assessed by using either 2-tailed nonparametric Mann-Whitney tests or 2-tailed parametric t tests and the Friedman test for multiple comparisons. Kruskal-Wallis and 2-way ANOVA tests were used in murine experiments for analyses of cytokine production and airway hyperreactivity measurements, respectively. Statistical analyses and graphic representations were performed with Prism 6 software (GraphPad Software, La Jolla, Calif).
RESULTS

Identification of biomarkers predictive of sublingual immunotherapy efficacy by means of quantitative proteomics
To identify markers predicting the clinical response to AIT, we combined 2D-DiGE and MS to assess differential protein expression in pretreatment sera obtained from 82 patients with grass pollen allergy receiving either grass pollen (n 5 42) or placebo (n 5 40) tablets sublingually once a day for 4 months (see Fig E1 and Table E1 in this article's Online Repository at www.jacionline.org). As a first step, we applied an arbitrary threshold corresponding to the median percentage of ARTSS improvement in the active group after treatment to stratify patients into 4 subgroups (see the Methods section), including ARs (n 5 21), ANRs (n 5 21), PRs (n 5 7), and PNRs (n 5 33).
Serum samples from these subgroups were compared in a blind manner by using 2D-DiGE (Fig 1, A) (Fig 1, C) and placebo (Fig 1, D) groups (left panels). *P < .05, **P < .01, or ***P < .001. Correlations of acidic protein spot volumes with ARTSS improvement in patients from the active (Fig 1, C) and placebo (Fig 1, D) groups (right panels) are shown. E, Abundances of acidic FetA spots were assessed by using 2D-DiGE before and after sublingual immunotherapy in sera from patients receiving placebo or active tablets.
protein spots were excised from 2-dimensional gels, digested with trypsin, and analyzed by using MS. In such analyses differences in levels of expression of the FetA protein (also termed a-2-HS-glycoprotein) were observed between pretreatment sera obtained from ARs and ANRs (Fig 1, A and B, and see Table E2 in this article's Online Repository at www. jacionline.org). Specifically, 4 FetA proteoforms (corresponding to spots 419, 428, 439, and 448) were highly expressed in pretreatment sera of ARs relative to that of ANRs (P < .01 to .001; Fig 1, B and C, left panel) , whereas the proteoform present in spot 469 was decreased (P < .05; Fig 1, B and C, left panel) . No such differences were observed in the placebo group (Fig 1, D, left  panel) . Percentages of symptom score improvement for each patient were then plotted against the abundance of the sum of acidic spots 428, 439, and 448 to validate those results obtained after patient stratification based on an arbitrary threshold of efficacy. These parameters were highly significantly correlated (with a Spearman correlation r 5 0.50, P 5 .0009) within the cohort of patients receiving active treatment (Fig 1, C, right panel) , whereas no such correlation was observed in placebo-treated patients (Fig 1, D, right panel) . It is noteworthy that we did not observe any variation in serum levels of FetA acidic forms in the course of AIT (Fig 1, E) , establishing that patterns of FetA proteoforms are tightly regulated as a characteristic of each patient. Collectively, these results suggest differences in the relative distribution of FetA proteoforms in pretreatment sera of ARs when compared with that of ANRs.
O-glycosylated sialylated FetA is highly abundant in pretreatment sera of clinical responders
FetA is a 60-kDa heterodimer between a 282-amino-acid A chain and a 27-amino-acid B chain assembled by a single disulfide bond. The protein bears both N-and O-linked oligosaccharide chains containing sialic acid residues (UniProtKB accession no. P02765). 24, 25 To further characterize human FetA proteoforms, we purified the molecule from sera of healthy subjects using affinity chromatography (see Fig E2 in (Fig 2, B, comparing FetA in green with AsialoFetA in red), thereby confirming that the presence of Neu5Ac results in a more acidic isoelectric point for the molecule. Although not shown, the heterogeneity of desialylated FetA is also due to various levels of serine and threonine phosphorylation.
Purified FetA was analyzed by using liquid chromatographymass spectrometry (LC-MS/MS) after digestion with trypsin to further characterize its glycosylation pattern. Tryptic glycopeptides were assigned based on accurate precursor and specific fragment ion mass measurements. For example, glycopeptides containing sialylated glycans yield B-type ions with neutral masses of 291.1 and 273.1 Da (corresponding to Neu5Ac and dehydrated Neu5Ac, respectively). Among the 5 glycosylation sites described in the literature, 24 residues N 156 and N 176 were confirmed to be substituted with N-glycan moieties harboring 2 sialic acid residues (ie, Hex 5 HexNAc 4 Neu5Ac 2 ; see Table E3 in this article's Online Repository at www.jacionline.org). Interestingly, O-glycopeptides (OGs) from the A chain bear 2 mucin-type glycans branched on residues T 256 and T 270 , each sialylated with 1 or 2 Neu5Acs, yielding variants with 2, 3, or 4 Neu5Acs subsequently termed OG1, OG2, and OG3, respectively (Fig 2,  C , and see Table E3 ). In addition, the B chain also encompasses nonsialylated, monosialylated, and disialylated forms with Neu5Ac attached to residue S 346 (see Fig E3, B-D) .
To confirm whether the shift toward acidic forms of FetA observed in ARs is related to sialylation levels, an MS analysis of FetA glycopeptides was conducted in sera from allergic patients (see Table E3 ). OGs containing 2 Neu5Acs were significantly increased in pretreatment sera from ARs relative to ANRs (including OG2: P < .05 and OG3: P < .001; Fig 3, A, left panel; disialylated B chain: P < .01; see Table E3 ). Importantly, abundances of the tetrasialylated glycopeptide OG3 (and, to a lower extent, the trisialylated glycopeptide OG2) before treatment were significantly correlated with clinical benefit in patients from the active group (with a Spearman correlation r 5 0.55, P 5 .0002; Fig 3, A, right panel), whereas no such correlations were observed in placebo-treated patients (Fig 3, B) . As shown in Fig E5 in this article's Online Repository at www.jacionline. org, a highly significant correlation was observed between OG3 peptide abundance and spot volumes (spots 428 1 439 1 449) in pretreatment sera of individual patients. Although not shown, total serum FetA concentrations (assessed by using either ELISA or label-free MS) were not correlated with clinical benefit, confirming that the predictive value is strictly linked to levels of O-glycosylated sialylated FetA. As shown in Fig 3, C, a receiver operating characteristic of OG3 abundance confirmed that this marker is useful to distinguish clinical responders from nonresponders (area under the curve, 0.8050; P 5 .0007).
In vivo silencing of the FETUA gene in BALB/c mice exacerbates allergen-induced inflammation
FetA is known as an acute-phase protein with either a protective or enhancing role in various forms of inflammation. 25 As of today, however, no specific role in allergic inflammation has been assigned to FetA. The FETUA gene was inactivated in BALB/c mice sensitized with OVA to investigate the potential effect of FetA in a murine model of allergic asthma. To this aim, a group of animals received multiple intravenous injections of a FetA-specific vivo-morpholino (Fig 4, A) by using naive (ie, nonsensitized) or untreated sensitized mice, as well as animals receiving an irrelevant morpholino as controls in those experiments. The efficacy of FetA silencing was confirmed by means of ELISA, with a 55.7% 6 13.3% (mean 6 SEM) decrease in FetA serum concentrations observed at day 9 compared with pretreatment values (P < .05) in animals receiving the FetA-specific vivo-morpholino (Fig 4, B) . In contrast, FetA levels remained stable over time in sera from naive or mock-treated animals (Fig 4, B) . FetA silencing resulted in exacerbated airway hyperresponsiveness (measured as an enhanced pause index) when compared with naive mice, untreated sensitized mice, or OVA-sensitized animals receiving the control morpholino (P < .0001; Fig 4, C) . As shown in Fig E6 in this article's Online Repository at www.jacionline.org, similar results were obtained in grass pollen-sensitized mice. These results were further confirmed by means of invasive plethysmography because animals with the FETUA gene inactivated exhibited a statistically significant (P < .05) increase in lung resistance compared with control animals (Fig 4, D) . In agreement with those results, production of IL-5, IL-10, and IL-13 T H 2 cytokines was significantly (P < .01) increased in splenocytes from FetAsilenced mice restimulated in vitro with OVA when compared with that in sensitized animals receiving the control morpholino (Fig 4, E) .
Sequence alignment revealed that murine FetA shares 59% amino acid identity with its human counterpart (see Fig E7 in 
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LGGAEVAVTCTVFQTQPVTSQPQPEGANEAVPTPVVDPDAPPSPPLGAPGLPPAGSPPDSHVLLAAPPGHQLHR (Fig 3, A) and placebo (Fig 3, B) groups. *P < .05 or ***P < .001. Correlations of OG3 abundance with ARTSS improvement in patients from the active (Fig 3, A) and placebo (Fig 3, B) groups (right panels) after sublingual immunotherapy are shown. C, Receiver operating characteristic (ROC) analysis of OG3 abundance in serum samples from patients of the active group. to 100 (n 5 3 mice per group). *P < .05. C, Airway hyperresponsiveness measured by using whole-body plethysmography is expressed as an enhanced pause (Penh) index (means 6 SEMs, n 5 6 mice per group). D, Lung resistance (Rl) was assessed by using invasive plethysmography (means 6 SEMs, n 5 6 mice per group). *P < .05 (*) or ****P < .0001. E, Cytokine secretion was assessed in splenocytes from animals untreated or treated with morpholinos (means 6 SEMs, n 5 6 mice per group). **P < .01. F, Identification by using LC-MS/MS of sialic acid-containing OGs associated with murine FetA. Yellow squares, N-acetylglucosamine; yellow circles, hexose; open diamonds, N-glycolylneuraminic acid (Neu5Gc). (Fig 5, F) or D farinae allergen extract (Fig 5, G) . Results are presented as means 6 SEMs (n 5 6 donors tested). *P < .05, ** P < .01, or ****P < .0001.
O-glycopeptide (mOG) 1, mOG2-A, mOG2-B, and mOG3, respectively (Fig 4, F , which is to be compared with Fig 2, C) .
FetA, but not AsialoFetA, synergizes with LPS in a TLR4-dependent pathway to enhance the proallergic profile of human MoDCs
FetA has been shown to promote lipid-mediated inflammation by acting as an adaptor molecule between free fatty acids and TLR4. [26] [27] [28] The engagement of TLR4 is known to enhance allergic inflammation, such as during concomitant exposure to allergens in the presence of endotoxins [29] [30] [31] or as a consequence of a functional mimicry of myeloid differentiation-2 (MD-2) by the allergen itself. 32 In this context we examined whether FetA could contribute to allergic inflammation in a TLR4-dependent manner and furthermore whether FetA sialylation would play a potential role in this regard. In a first set of experiments, functional interactions between FetA and TLR4 were examined by using HEK-293 cells expressing both human TLR4 and a reporter alkaline phosphatase gene inducible after TLR activation. Those human TLR4 HEK-293 cells were first stimulated with LPS, FetA at various doses, or a mixture of both. As shown in Fig 5, A, FetA alone had no effect, whereas a combination of FetA and LPS acted in synergy to engage TLR4 in a dose-dependent manner. We subsequently compared FetA and AsialoFetA (ie, neuraminidase-treated FetA, with complete desialylation confirmed by using LC-MS; see Fig E4) for their capacity to synergize with LPS in this cellular assay. The synergistic modulation of TLR4 activity by LPS was substantially decreased when human TLR4 HEK-293 cells were costimulated with AsialoFetA as opposed to FetA (Fig 5, B) .
Immature MoDCs were cultured in serum-free medium (to preclude exposure to FetA from bovine serum) supplemented with a mixture of histamine, IL-25, IL-33, prostaglandin E 2 , thymic stromal lymphopoietin, and low doses (10 ng/mL) of LPS to investigate further the potential effect of FetA sialyl forms on TLR4-mediated allergic inflammation. In our hands those conditions (termed the DC2 cocktail) drive the differentiation of MoDCs toward a DC2 phenotype (ie, capable of polarizing naive CD4
1 T cells toward IL-5-and IL-13-secreting T H 2 cells). 15 A flow cytometric analysis confirmed an upregulation in such DCs of CD83 and CD86 costimulatory markers in the presence of FetA but not AsialoFetA (Fig 5, C) . Similarly, DCs differentiated in the presence of FetA secreted significantly higher levels of IL-6, IL-8, IL-10, and TNF-a when compared with AsialoFetA-treated DCs (Fig 5, D) . It is noteworthy that the synergy observed between LPS and FetA in those assays was totally abrogated by adding the TLR4 antagonist LPS-RS (data not shown), 33 confirming that FetA and LPS act in combination to activate the TLR4 pathway. Furthermore, expression by DCs of a gene associated with DC2 polarization (ie, PADI2) 15 was upregulated in the presence of FetA but not AsialoFetA (Fig 5, E) . In contrast, expression of genes associated with DCs driving the differentiation of T H 1 cells or DCReg differentiation, such as MX1 or C1QA, respectively, 14 was strongly downregulated when DCs were cultured in the presence of FetA but not AsialoFetA (Fig 5, E) . In addition, after stimulation of immature MoDCs with a grass pollen extract or a house dust mite Dermatophagoides farinae extract in combination with either FetA or AsialoFetA, only the former synergized with the allergen extracts to induce the secretion of IL-6, IL-10, and TNF-a cytokines, whereas no such effect was observed with AsialoFetA (Fig 5, F and G) . Synergy with FetA, but not AsialoFetA, was also detected for IL-8 secretion by immature MoDCs when stimulating with the grass pollen in contrast to the D farinae allergen extract because levels of IL-8 (Fig 6, A) or AsialoFetA (Fig 6,  B) immobilized on CM5 sensor chips. C-E, Sensorgrams obtained after injection of either LPS (Fig 6, C) , a combination of LPS with FetA (Fig 6, D) or LPS with AsialoFetA (Fig 6, E) over TLR4-MD-2 immobilized on a CM5 sensor chip. Sensorgrams are represented as response units (RUs) at specified times in seconds.
J ALLERGY CLIN IMMUNOL VOLUME 140, NUMBER 3 produced were already very high with the latter allergen alone (Fig 5, F and G) . Altogether, those experiments establish that FetA can enhance the proallergic profile of DCs exposed to natural allergens in relationship to its level of sialylation.
Using surface plasmon resonance, we subsequently investigated the potential physical interactions between FetA (or AsialoFetA), LPS, and TLR4-MD-2. Both FetA and AsialoFetA were found to bind LPS in a comparable dosedependent manner (Fig 6, A and B) . In contrast, neither FetA nor AsialoFetA had any detectable effect on the physical interaction of LPS with TLR4-MD-2 complexes (Fig 6, C-E) .
DISCUSSION
AIT is a well-established treatment for type I respiratory allergies, inducing a long-lasting reduction of symptoms in association with a downregulation of allergen-specific T H 2 responses.
1-3,9-11,34 As of today, however, less than one third of patients who could benefit from AIT are proposed for use of this therapy 35 on the basis of their symptom severity, reactivity to skin prick tests, and/or high titers of allergen-specific IgEs. 1, [16] [17] [18] [19] [20] [21] [22] Patient selection and compliance would be improved significantly if predictive biological markers were available to identify those subjects more likely to benefit from AIT.
To address this need, we performed a comparative proteomic analysis on pretreatment sera obtained from 82 patients with grass pollen allergy included in a double-blind placebo-controlled clinical study performed in an allergen challenge chamber. 23 In this study up to 30% symptom score improvement was observed in the active group relative to the placebo group after 4 months of sublingual AIT. 23 Importantly, symptom scoring of each patient before and after AIT allowed us to distinguish clinical responders from nonresponders. Comparative analyses of serum proteomes by using 2D-DiGE combined with LC-MS/MS established that FetA acid glycoforms are differentially expressed before treatment in sera from ARs relative to that from ANRs. Consistent with the known existence of posttranslational modifications on FetA, 24, 25, [36] [37] [38] we established that sialic acid (Neu5Ac) residues are responsible for the shift toward acidic isoelectric point of FetA isoforms observed in sera from ARs. A comprehensive MS characterization further confirmed that levels of tetrasialylated OG3 from FetA before treatment positively correlate (P < .0002) with clinical improvement during subsequent AIT.
FetA is an abundant blood protein produced in the liver, with multiple functions linked to its capacity to bind ligands as diverse as calcium, TGF-b, the insulin receptor, free fatty acids, and TLR4. 25 As a mineral carrier protein, it is involved in the regulation of osteogenesis and the prevention of vascular calcification. 39, 40 FetA also inhibits insulin receptor tyrosine kinase activity, contributing to metabolic disorders, such as insulin resistance and dyslipidemia. 27, 41 In murine models, FetA often mediates protective anti-inflammatory activity, such as against cerebral ischemic injury or lethal sepsis. 42, 43 In human pathology the protein is considered either to be a negative or positive acute-phase protein because many inflammatory conditions are associated with either a decrease (eg, trauma, rheumatoid arthritis, infection, kidney disease, hematological malignancies, or myocardial infarction) 25, 37, [44] [45] [46] or an increase (eg, obesity, type 2 diabetes, or ischemic stroke) 25, [47] [48] [49] in serum FetA levels. Although measurement of FetA levels in the blood is already used as a prognostic marker for some of those conditions, little is known about the significance of its posttranslational modifications. Also, whereas the existing body of scientific literature supports the notion that FetA can act either as an inhibitor or promoter of chronic inflammation, up to now, no specific role had been ascribed to it in patients with T H 2-mediated allergic inflammation.
Herein we demonstrate that silencing of the gene encoding FetA in a murine model of allergic asthma results in exacerbated allergic inflammation, thus revealing a strong anti-inflammatory activity of FetA in this experimental setting. However, this observation is not easily transposable to human allergies because murine and human FetA molecules differ significantly, with only 59% homology in their amino acid sequences (see Fig E5) . Also, murine FetA lacks the sialylated O-glycans found in the human protein (Figs 2, C, and Fig 4, F) . When testing the functionality of human FetA, we established in both human TLR4 HEK-293 and human DC models that FetA synergizes with LPS to activate TLR4, consequently promoting the differentiation of MoDCs into proallergic DC2s, the secretion of proinflammatory cytokines, and the downregulation of genes associated with DCs, driving the differentiation of T H 1 or DCReg cells. Further supporting a role of human FetA in patients with allergic inflammation, the latter was found to increase TLR4 activation by grass pollen or house dust mite extracts, which are known to contain both allergens and endotoxins. 29, 30, 50 Interestingly, this synergistic activation of the TLR4 pathway was largely diminished for neuraminidase-treated FetA, highlighting the key role of sialic acids branched on glycans in this proallergic cascade. In agreement with the recent identification of FetA as a central adaptor molecule contributing to fatty acid-mediated inflammation, our study confirms the capacity of FetA to interact with the TLR4 pathway and induce nuclear factor kB (NF-kB)-driven genes. 27 Surface plasmon resonance documented that both FetA and AsialoFetA bind similarly to LPS, without evidence in our hands for any strong binding to the TLR4-MD-2 complex. How sialylation of FetA influences functional activation of TLR4 is presently unclear but is consistent with a previous observation that removal of N-and O-linked b-galactosides bearing sialic acid residues abrogates the interaction of FetA with TLR4. 27 It is noteworthy that a reduced sialylation of blood FetA has been reported in neonates with intrauterine growth restriction 51 and in patients with rheumatoid arthritis. 38 Despite the new evidence presented in this study that sialylated human FetA amplifies allergic inflammation, it is still unclear why the persistence of sialylated forms of FetA in patients' sera might be predictive of clinical benefit during AIT. A high degree of FetA sialylation could reflect a higher reactivity to allergens because of a stronger engagement of the proinflammatory TLR4 pathway. Indeed, patients with high levels of sialylated FetA tend to exhibit more severe rhinoconjunctivitis symptoms before treatment (data not shown), which is known to favor clinical improvement during AIT. 17 One potential limitation to the use of FetA as a biomarker predictive of AIT efficacy is that this protein plays a ubiquitous role in many aforementioned inflammatory conditions associated with quantitative variations of blood FetA levels. 25, [44] [45] [46] [47] [48] [49] Remarkably, however, we observed highly stable levels of FetA acidic variants in the blood of patients with grass pollen allergy over the 4 months of our study, irrespective of allergen exposure either in the pollen chamber or during the course of AIT. This suggests that levels of sialylated FetA in the blood are tightly regulated and might reflect the own capacity of each patient to mount and/or resolve inflammatory reactions. Validation of the hypothesis that a marker associated with ''an inflammation status'' can be used to predict AIT efficacy is ongoing in larger cohorts of patients naturally exposed to either seasonal (pollens) or perennial (house dust mites) allergens.
Clinical implications: FetA plays either an inhibiting or amplifying role in allergic inflammation, depending on posttranslational modifications of the molecule. Patients with high levels of sialylated FetA glycoforms in their blood before treatment are more likely to benefit from grass pollen immunotherapy.
METHODS Study approval
The VO56.07 clinical study was carried out in accordance with international good clinical practice and was approved by both an independent ethics committee and regulatory authorities (ClinicalTrials.gov identifier: NCT00619827). All patients provided written informed consent before study entry. For mouse studies, international standards were applied for animal handling, and animal protocols were validated by an internal ethics committee.
Serum depletion
Serum samples (340 mL each) from patients with grass pollen allergy were depleted from the 6 most abundant proteins by using a human Multiple Affinity Removal System Human 6 (Hu-6HC column, 10 3 100 mm; Agilent Technologies, Palo Alto, Calif) and an Ultimate 3000 HPLC apparatus (Thermo Scientific, Waltham, Mass). Flow-through proteins were collected and concentrated according to the manufacturer's instructions. After depletion, samples were stored at 2808C until analysis. The run-to-run reproducibility of depletion was confirmed by means of chromatography and SDS-PAGE analyses under reducing conditions by using 4-12% NuPAGE gels, according to the manufacturer's instructions (Thermo Scientific).
2D-DiGE-based proteomics
Protein samples from depleted sera were precipitated by using a 2-dimensional clean-up kit according to GE Healthcare's (Fairfield, Conn) protocol, with precipitates resolubilization in a buffer containing 7 mol/L urea, 2 mol/L thiourea, 4% CHAPS, and 30 mmol/L Tris (pH 8.8; all obtained from Sigma-Aldrich, St Louis, Mo) and stored at 2808C. Protein concentrations were determined by using the Bradford assay (Bio-Rad Laboratories, Hercules, Calif), and 50 mg of depleted serum proteins was labeled with 400 pmol of either Cy2, Cy3, or Cy5 dyes (GE Healthcare), as described in the instruction manual. A dye-swapping scheme was used to preclude any specific dyelabeling artifact. The Cy2-labeled internal standard was obtained by pooling equal amounts (25 mg) of proteins from all 82 depleted sera. Protein samples labeled with Cy2, Cy3, and Cy5 dyes were mixed and diluted with a rehydration buffer containing 7 mol/L urea, 2 mol/L thiourea, 4% CHAPS, 100 mmol/L dithiothreitol (DTT), and 0.5% immobilized pH gradient solution (IPG) at a final volume of 450 mL. Proteins (150 mg) were then applied to 24-cm-long immobilized pH 4-7 gradient strips (GE Healthcare), according to the manufacturer's instructions. Isoelectric focusing was performed for a total of 74 kVh by using an IPGPhor 3 electrophoresis unit (GE Healthcare) cooled to 188C. Strips were then equilibrated in urea-containing buffer and placed on top of precast SDS 12.5% polyacrylamide gels (GE Healthcare). Electrophoresis was carried out at 0.5 W for 1 hour, followed by 1 W for 16 hours (by using an Ettan DALT Twelve Electrophoresis System, GE Healthcare). DiGE gels were scanned with an Ettan DiGE Imager (GE Healthcare), according to the manufacturer's instructions. Differentially expressed spots were determined by means of image analysis with the SameSpots program (v4.1; Nonlinear Dynamics) and selected for automatic spot picking (EXquest Spot Cutter, BioRad Laboratories). Preparative gels stained with SYPRO Ruby (Thermo Scientific) were used for spot picking and protein identification by using tandem mass spectrometry (MS/MS).
To this aim, gel plugs were digested with trypsin (from porcine pancreas, Sigma Aldrich), and the resulting peptides were separated by means of reversed-phase chromatography with an Ultimate 3000 RS-nanoLC system (Thermo Scientific) coupled to a high-resolution Maxis 4G ESI-Qq-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany). Peptides were injected and trapped on an Acclaim PepMap100 column (100 mm 3 2 cm; C 18 , 5-mm particles, and pore size at 100 A; Thermo Scientific), followed by separation with a C 18 column (Acclaim PepMap RSLC 75 mm ID, 15 cm, 2-mm particles, and pore size at 100 A; Thermo Scientific). NanoLC-MS/MS data were analyzed by using an in-house Mascot server (v2.3; Matrix Science, London, United Kingdom) or PEAKS software (v7; Bioinformatics Solutions, Waterloo, Ontario, Canada) to search the UniprotKB/TrEMBL and nonredundant National Center for Biotechnology Information databases (downloaded December 2013), assuming tryptic digestion. Precursor and fragment masses were searched with a mass tolerance of 8 ppm and 0.05 Da, respectively. The search included fixed modification of carbamidomethyl cysteine. The minimal peptide length was set to 6 amino acids, with a single miscleavage allowed. Peptide identifications were accepted when established with a probability of 95% or greater, as specified by Mascot or PEAKS software.
Label-free MS-based proteomics
Fifty micrograms of depleted serum proteins were solubilized in a buffer containing 8 mol/L urea and 75 mmol/L Tris (pH 8.5), reduced, and alkylated with 20 mmol/L DTT and 50 mmol/L iodoacetamide, respectively, and digested with trypsin (1:25 wt/wt) at 378C overnight. Peptides were then acidified with 2.5% formic acid (FA) and analyzed by means of LC-MS/MS with the Ultimate 3000 RSLC system (Thermo Scientific) coupled to the ESIQq-TOF mass spectrometer. Five micrograms of tryptic peptides was injected on an ACQUITY C 18 BEH130 column (10 mm ID, 10 cm, 1.7-mm particles; Waters, Milford, Mass) equilibrated at 408C with 95% solvent A (0.15% FA) and 5% solvent B (100% Acetonitrile [ACN] and 0.15% FA) at a flow rate of 0.4 mL/min. Peptide separation was performed at a flow rate of 0.4 mL/min, with a linear gradient obtained by using 5% to 40% solvent B over 30 minutes. Ion intensities recorded in LC-MS data were analyzed with Progenesis LC-MS v4.1 software (Nonlinear Dynamics) to provide reliable measurements of peptide abundance across samples. Lock mass calibration and peptide detection were performed with a peptide intensity of greater than 1000, peptide abundance of greater than 2000, and peptide charge between 21 and 121. Data were then normalized by the ''normalize to all features'' method, and peptides differentially represented in samples obtained from the 4 patient subgroups (ie, ARs, ANRs, PRs, and PNRs) were identified. LC-MS/MS data were analyzed by using an in-house Mascot server against the Swiss-Prot database, taxonomy Homo sapiens, assuming tryptic digestion, as described above.
Characterization of human FetA and AsialoFetA
FetA was purified from pooled sera obtained from AB 1 subjects (Lonza, Walkersville, Md) diluted 1:10 vol/vol in 13 PBS. Affinity chromatography was performed by using a human FetA-specific murine mAb (clone 162919; R&D Systems, Minneapolis, Minn) coupled to a 5-mL HiTrap affinity column pre-equilibrated in binding buffer (13 PBS, pH 7.4). After loading samples at a flow rate of 0.8 mL/min, the column was washed with 8 volumes of binding buffer until the OD 214 decreased to less than 5% of its maximum value. FetA was eluted by running 7 volumes of 50 mmol/L glycine-HCl (pH 3) at a flow rate of 1 mL/min, followed by neutralization with 1 mol/L Tris-HCl (pH 9). Subsequently, samples were diafiltered and concentrated by using an Amicon ultra-15 mL membrane with a cutoff of 10 kDa (Millipore, Billerica, Mass) before SDS-PAGE (4-12% NuPAGE gel; Thermo Scientific) and Western blotting analysis with an anti-FetA mAb (R&D Systems), followed by an anti-mouse sheep IgG-peroxidase antibody (Sigma-Aldrich) for revealing. For desialylation, 31.2 mg of native purified FetAwere mixed with 10 mL of 5X Reaction Buffer and 1 mL of a-(2/3,6,8,9)-Neuraminidase (EDEGLY Kit; Sigma-Aldrich) to reach a final enzymatic activity of 0.109 U/mL. The mixture was incubated overnight at 378C, and complete desialylation was confirmed by using SDS-PAGE (4-12% NuPAGE gel; Thermo Scientific) and MS characterization. AsialoFetA samples were run on Detoxi-Gel Endotoxin Removing Columns (Thermo Scientific), according to the manufacturer's instructions. Levels of endotoxin in FetA and AsialoFetA samples controlled by using a chromogenic Limulus Amebocyte Lysate assay (LAL Chromogenic Endotoxin Quantitation Kit; Thermo Scientific) were always less than 0.0002 EU/mg.
Measurements of the average mass of intact purified FetA or AsialoFetA were performed on a Maxis ESI-Qq-TOF mass spectrometer coupled to an Ultimate 3000 RSLC system (Thermo Scientific). Proteins were denatured and reduced in a buffer containing 8 mol/L urea, 75 mmol/L Tris (pH 8.5), and 20 mmol/L DTT for 20 minutes and acidified by using 2.5% FA. Protein samples were then desalted and concentrated for 4 minutes onto an ACQUITY C 4 BEH300 column (10 mm ID, 10 cm, 1.7-mm particles; Waters) equilibrated at 708C with 95% solvent A (0.15% FA) and 5% solvent B (100% ACN and 0.15% FA) at a flow rate of 0.4 mL/min. Proteins were eluted directly into the mass spectrometer with a linear gradient from 5% to 60% solvent B over 30 minutes. Mass spectra were deconvoluted with MaxEnt software, and the precise average mass of proteins was determined with Data Analysis software (v4.2; Bruker Daltonics).
Posttranslational modifications of purified FetA or AsialoFetA were determined by using nanoLC-MS/MS, as described above. Purified proteins were solubilized in a buffer containing 8 mol/L urea, 75 mmol/L Tris (pH 8.5), and 5 mmol/L Tris(2-carboxyethyl)phosphine (TCEP). Proteins were then alkylated with 10 mmol/L iodoacetamide for 20 minutes and digested in solution with trypsin (1:50 wt/wt) for 3 hours at 378C in the presence of 0.02% ProteaseMax surfactant (Promega, Madison, Wis). Subsequently, 2.5% FA was added to the mixture to quench enzymatic activity, and peptides were stored at 2808C until analysis. Peptide samples were then spun at 18,000g and run on a C18 column (Acclaim PepMap RSLC 75 mm ID, 25 cm, 2-mm particles, and pore size at 100 A; Thermo Scientific). N-glycopeptides and OGs were manually characterized based on the presence of glycan-specific oxonium ion fragments by using Data Analysis software.
Characterization of murine FetA
Murine FetA was enriched from serum from BALB/c mice by means of immunocapture with an anti-murine FetA mAb (clone DY1563; R&D Systems) covalently linked to magnetic beads (Dynabeads M-280; Thermo scientific). This bead suspension was incubated for 2 hours with sera from BALB/c mice diluted in PBS (1:1 vol/vol) and washed twice with PBS, and proteins were eluted with a 50% ACN and 0.1% trifluoroacetic acid solution. FetA immunoprecipitates were dried by means of vacuum centrifugation and resuspended in 50 mmol/L ammonium bicarbonate buffer (pH 8.0). After reduction with 45 mmol/L DTT at 608C for 30 minutes and alkylation with 100 mmol/L iodoacetamide at room temperature for 45 minutes, samples were incubated overnight at 378C with 1 mg of trypsin. After quenching with FA (0.5% vol/vol final), samples were injected into a C18 column (Acclaim PepMap RSLC 75 mm ID, 25 cm, 2-mm particles, and pore size at 100 A; Thermo Scientific). The column effluent was directly introduced into the electrospray source of an ImpactHD ESI-Qq-TOF mass spectrometer (Bruker Daltonics). Characterization of the glycosylation pattern was performed manually by using the Data Analysis software.
Evaluation of immunomodulatory properties of FetA and AsialoFetA
In vivo silencing of the gene encoding FetA was performed in female BALB/c mice (6-8 weeks of age; Charles River, Wilmington, Del) to assess its effect on allergic inflammation. Mice were sensitized with an intraperitoneal injection of 10 mg OVA (Sigma-Aldrich) adsorbed on 2 mg of Al(OH) 3 , followed by a 20-minute aerosol challenge at days 7 and 8 by using 50 mg of OVA per mouse. Alternatively, naive mice were sensitized through the intraperitoneal route with a timothy grass pollen extract (using a dose containing 10 mg of Phl p 5; Stallergenes SA, Antony, France) mixed with alum, followed by 2 intranasal challenges with the timothy grass pollen extract in PBS (equivalent to 10 mg of Phl p 5) performed on days 7 and 8 after the first immunization. In both experimental settings, FetA silencing was achieved by means of 4 intravenous injections of a specific vivo-morpholino (59-AAGAC CAGGGACTTCATGGTTGCTC-39; Gene Tools, Philomath, Ore) by using 40 nmol/L 1 day before sensitization and 25 nmol/L at days 2, 5, and 7. A standard irrelevant vivo-morpholino sequence was used in parallel for mock treatment of control animals.
E1 Measurements of airway hyperresponsiveness were performed by using whole-body plethysmography with a Buxco (Wilmington, Del) apparatus after exposure to increasing doses (0-50 mg/mL) of nebulized methacholine and determination of enhanced pause values.
E2
Lung resistance was measured with a FinePointe Resistance and Compliance system (Buxco), and mice were subsequently killed. Serum FetA levels were assessed by means of ELISA (R&D Systems) on retro-orbital bleeds at 4 time points during sensitization and after death. Splenocytes were stimulated with either 100 mg/mL OVA or medium for 72 hours at 378C under a 5% CO 2 atmosphere, and cell supernatants were collected to measure IL-5, IL-10, IL-13, and IFN-g concentrations by using a Luminex assay (Millipore, Temecula, Calif).
Monocytes isolated from PBMCs of healthy volunteers with CD14 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were cultured in the presence of GM-CSF and IL-4 (Miltenyi Biotec) for 6 days. DC differentiation was confirmed by mean of flow cytometry based on loss of CD14 expression and upregulation of CD1a and CD11c surface expression. Immature MoDCs or MoDCs polarized toward a DC2 pattern (using a mixture of histamine, IL-25, IL-33, thymic stromal lymphopoietin, and 10 ng/mL LPS) were cultured in serum-free medium (CellGro DC medium; CellGenix, Freiburg, Germany) E3 for 24 hours in the presence of either medium alone or medium supplemented with purified native FetA (10 mg/mL), AsialoFetA (10 mg/mL), a grass pollen, D farinae allergen extract (20 or 1 mg/mL, respectively; Stallergenes SA), or combinations of these reagents. The TLR4 signaling pathway was blocked by adding LPS from Rhodobacter sphaeroides (LPS-RS, 10 mg/mL; InvivoGen, Toulouse, France) to the cultures for 30 minutes. Supernatants were harvested to measure cytokine (IL-1b, IL-6, IL-8, IL-10, IL-12p70, and TNF-a) production by using a Luminex assay (Milliplex, Millipore). Surface expression of maturation markers (CD80, CD83, and CD86) was assessed on DCs by using flow cytometry with specific antibodies (BD Biosciences, San Jose, Calif). Total RNA (RNeasy Mini Kit; Qiagen, Venlo, The Netherlands) was isolated to evaluate expression of the C1QA, MX1, and PADI2 genes by using real-time PCR E4 with b-actin as an endogenous reference gene and the following primers, respectively, all from Thermo Scientific: Hs00381122_m1, Hs00895608_m1, and Hs00247108_m1.
Analysis of LPS-FetA-TLR4 interactions
The interaction between FetA and TLR4 was analyzed with HEK-293 epithelial cells expressing the human TLR4 receptor together with a reporter gene driven by an NF-kB inducible promoter encoding an alkaline phosphatase secreted after TLR activation. Human TLR4 HEK-293 cells were incubated for 18 hours with either ultrapure LPS-EB from Escherichia coli (100 ng/mL; InvivoGen), purified native FetA (10 mg/ml), AsialoFetA (10 mg/mL), or combinations of these reagents, and TLR activation was then quantified by measuring ODs of culture supernatants at 655 nm.
Surface plasmon resonance experiments were performed on a Biacore T200 Instrument (GE Healthcare) with HC200m (CM5 type) sensor chips, according to the manufacturer's instructions. Briefly, proteins were immobilized on the HC200m sensor chip using by the amine-coupling method to reach 1500 and 2500 response units of immobilized FetA and AsialoFetA, respectively. Blocking of the reference flow cell was performed by means of activation, followed by immediate quenching, as for the active flow cell. A running buffer containing 10 mmol/L HEPES (pH 7.4), 150 mmol/L NaCl, and Tween (0.05% vol/vol) was used in all experiments, with a flow rate of 10 to 30 mL/min. LPS was injected at various concentrations (13- .07A study design. Schematic design of the pollen chamber trial. After screening and randomization, 82 patients with grass pollen allergy were treated sublingually once daily with either a placebo (n 5 40) or a grass pollen (n 5 42) tablet for 4 months. Grass pollen challenges were performed before treatment (at inclusion), at day 7, and at months 1, 2, and 4 during AIT, with an evaluation of ARTSS during the 4 hours after challenge. The search for predictive biomarkers was performed on serum samples collected from patients before treatment initiation. Fig 2, A) . B-D, MS analysis of FetA B chain. Nonglycosylated (Fig E3, B) and sialylated forms (on O-linked glycans) are observed in the mass spectra ( Fig E3, C and D (Fig E4, B) and B chains (Fig E4, C and D Mice received intravenous injections of either specific vivo-morpholinos or controls at days 21, 2, 5, and 8 to silence FetA expression. i.n., Intranasal; i.p., intraperitoneal; i.v., intravenous. B, Airway hyperresponsiveness determined by using whole-body plethysmography was measured in response to increasing concentrations of methacholine, with results expressed as an enhanced pause (Penh) index as means 6 SEMs (n 5 6 mice per group). * P < .05, ** P < .01, and **** P < .0001. 
